Teladoc Health (NYSE:TDOC) PT Raised to $10.00 at Jefferies Financial Group

Teladoc Health (NYSE:TDOC) had its price target raised by equities research analysts at Jefferies Financial Group from $8.00 to $10.00 in a research report issued on Tuesday, Briefing.com reports. The brokerage currently has a “hold” rating on the health services provider’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 22.47% from the stock’s current price.

TDOC has been the topic of a number of other reports. JPMorgan Chase & Co. decreased their target price on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating on the stock in a research report on Monday, August 26th. Piper Sandler decreased their price objective on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. DA Davidson lowered their target price on Teladoc Health from $12.00 to $8.00 and set a “neutral” rating for the company in a research report on Thursday, August 1st. Stifel Nicolaus reduced their price target on shares of Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, August 1st. Finally, Truist Financial decreased their price target on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a research note on Friday, August 2nd. Fifteen analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.31.

Teladoc Health Trading Up 0.9 %

Teladoc Health stock opened at $8.17 on Tuesday. Teladoc Health has a 1 year low of $6.76 and a 1 year high of $22.54. The firm’s 50 day moving average price is $8.05 and its 200-day moving average price is $11.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.62. The stock has a market cap of $1.40 billion, a P/E ratio of -5.79 and a beta of 0.90.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. The company had revenue of $642.44 million for the quarter, compared to the consensus estimate of $649.34 million. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. On average, equities analysts predict that Teladoc Health will post -0.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Teladoc Health

In other news, CEO Laizer Kornwasser sold 10,879 shares of Teladoc Health stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $88,555.06. Following the completion of the sale, the chief executive officer now directly owns 99,929 shares in the company, valued at $813,422.06. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Teladoc Health news, CFO Mala Murthy sold 8,750 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.16, for a total transaction of $62,650.00. Following the transaction, the chief financial officer now directly owns 85,767 shares in the company, valued at approximately $614,091.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laizer Kornwasser sold 10,879 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $88,555.06. Following the completion of the sale, the chief executive officer now owns 99,929 shares of the company’s stock, valued at $813,422.06. The disclosure for this sale can be found here. Insiders have sold 57,819 shares of company stock valued at $442,204 in the last quarter. 0.95% of the stock is owned by insiders.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP purchased a new position in Teladoc Health during the 2nd quarter valued at about $45,267,000. Point72 Asset Management L.P. raised its stake in shares of Teladoc Health by 221.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock worth $51,865,000 after acquiring an additional 3,655,436 shares in the last quarter. Clearline Capital LP boosted its stake in Teladoc Health by 395.6% in the second quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after acquiring an additional 3,483,665 shares in the last quarter. Vanguard Group Inc. grew its holdings in Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after purchasing an additional 1,855,480 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Teladoc Health by 25.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after purchasing an additional 767,999 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.